Next Article in Journal
Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer
Next Article in Special Issue
The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review
Previous Article in Journal
Comparison of Five Oral Cannabidiol Preparations in Adult Humans: Pharmacokinetics, Body Composition, and Heart Rate Variability
Previous Article in Special Issue
The Effect of Novel Oleanolic Acid Oximes Conjugated with Indomethacin on the Nrf2-ARE And NF-κB Signaling Pathways in Normal Hepatocytes and Human Hepatocellular Cancer Cells
Review

Lenvatinib for Hepatocellular Carcinoma: A Literature Review

1
Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, 564-1 Kamishindenmachi, Maebashi, Gunma 371-0821, Japan
2
Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, 36 Takamatsucho, Takasaki, Gunma 370-0829, Japan
3
Department of Clinical Research, National Hospital Organization Takasaki General Medical Center, 36 Takamatsucho, Takasaki, Gunma 370-0829, Japan
4
Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(1), 36; https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010036
Received: 24 November 2020 / Revised: 1 January 2021 / Accepted: 3 January 2021 / Published: 6 January 2021
(This article belongs to the Special Issue New Therapies for Hepatocellular Carcinoma)
Lenvatinib, which is an oral multikinase inhibitor, showed non-inferiority to the sorafenib in terms of overall survival (OS) and a higher objective response rate (ORR) and better progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC). A good liver function and Barcelona Clinic Liver Cancer (BCLC) intermediate stage were the key factors in achieving therapeutic efficacy. The management of adverse events plays an important role in continuing lenvatinib treatment. While sequential therapies contributed to prolonging overall survival, effective molecular targeted agents for the administration after lenvatinib have not been established. Repeated transcatheter arterial chemoembolization (TACE) was associated with a decline in the liver function and poor therapeutic response in BCLC intermediate patients. Recently, the Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement proposed the criteria for TACE unsuitability. Upfront systemic therapy may be better for the BCLC intermediate stage HCC patients with a high tumor burden, while selective TACE will be recommended for obtaining a curative response in patients with a low tumor burden. This article reviews the therapeutic response, management of adverse events, post-progression treatment after Lenvatinib, and treatment strategy for BCLC intermediate stage HCC. View Full-Text
Keywords: lenvatinib; hepatocellular carcinoma; progression-free survival; overall survival; adverse events; post-progression treatment; BCLC intermediate stage; transcatheter arterial chemoembolization; nutrition assessment; sarcopenia lenvatinib; hepatocellular carcinoma; progression-free survival; overall survival; adverse events; post-progression treatment; BCLC intermediate stage; transcatheter arterial chemoembolization; nutrition assessment; sarcopenia
Show Figures

Figure 1

MDPI and ACS Style

Hatanaka, T.; Naganuma, A.; Kakizaki, S. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals 2021, 14, 36. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010036

AMA Style

Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals. 2021; 14(1):36. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010036

Chicago/Turabian Style

Hatanaka, Takeshi, Atsushi Naganuma, and Satoru Kakizaki. 2021. "Lenvatinib for Hepatocellular Carcinoma: A Literature Review" Pharmaceuticals 14, no. 1: 36. https://0-doi-org.brum.beds.ac.uk/10.3390/ph14010036

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop